2025 Q4 -tulosraportti
Vain PDF
28 päivää sitten
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 719 | - | - | ||
| 794 | - | - | ||
| 54 | - | - | ||
| 58 | - | - | ||
| 4 206 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·30 min sitten"THE NEW BEAST" HAS AWAKENED – ARE YOU READY FOR CIRCULAR DOMINANCE? 🦁🧬💎 If you were wondering if the hype is real, check today's headlines from Boston. BioWorld (the biotech bible) has just delivered its verdict: Circular RNA is "The New Beast" in gene and cell therapy. This is why those who sell now will bitterly regret it: 1. FROM THEORY TO INDUSTRIAL STANDARD 🏭 When the world's leading trade press uses words like "The New Beast", it means that mRNA 1.0 is about to be retired. Circio holds the keys to this new infrastructure. We're not talking about a small project, we're talking about the next technological monopoly. 2. THE 40X POWER THAT SHAKES BOSTON 💥 While you were reading the article, Circio presented poster data today confirming ~40x increased performance in heart tissue. These are numbers that make Big Pharma choke on their coffee. That's why we've got an ORAL PRESENTATION on Friday – the elite wants to hear it from the source. 3. THE VALIDATION TSUNAMI 🌊 • Acuitas collaboration: Checked. • 250 million in cash until 2030: Checked. • Global "Beast"-status: CONFIRMED. Status: Oslo Børs is taking a holiday, but the global biotech world has just hit the gas. We are in a company that is priced like a mosquito, but has the technology of a lion. Those who try to trade this in penny dips now are playing with matches in the middle of a gasoline explosion. We are not looking at the price. We are looking at the revolution. We know what we own. ♟️🧱🍷- ·38 min sittenTHE MATH BEHIND AN EXPLOSION – ARE YOU GEARED FOR TRIPLE DIGITS? 🧮🚀💎 Stop guessing. Start calculating. Those who see Circio as a "small biotech" haven't understood how platform pricing works when the pieces fall into place. With ~238 million shares outstanding, this is the calculation that should keep the bears awake at night. Here is the Bull-Case Matrix, from realistic to total euphoria: 1. PLATFORM RECOGNITION (20–50 kr) 🏗️ When the market understands that circVec is not just a project, but infrastructure for the next generation of RNA. The ASGCT data validates us, partnerships land, and 5–10 billion in Market Cap becomes the new normal. This is not "insanity" – it's fair pricing of unique tech. 2. BIG PHARMA MANIA (80–160 kr) 🏛️🔥 This is where it starts to get fun. Multiple deals, Acuitas credibility and in-vivo CAR-T data hitting the bullseye. International funds come in and sweep up what's left of the shares. Oslo Børs can no longer price the case – we're talking strategic acquisition pricing. 3. THE MOON SHOT (300 kr+) 🌕 Full circular revolution. Acquisition interest from the biggest giants who must own the technology not to die out. This is the scenario where those who sold at 10 kr will cry for decades to come. WHY IS THIS HAPPENING NOW? ⚡ • Cash Runway: 250 million in the back until 2030. The brakes are removed. • Oral Presentation: We own the main stage in Boston. • Small Valuation vs. Enormous Potential: This is the discrepancy we are exploiting now. Important message: Biotech is not for cowards. It's psychology, it's volatile, and it's brutal. But when the technology is real, and the Fibonacci lines point upwards, then it's mathematical gravity that takes over. We are not looking at small change. We are looking at a repricing of historical dimensions. The calculation is made. The seed is sown. We know what we own. ♟️🧱🍷
1 t sitten1 t sitten·49 min sitten · MuokattuThis is absolutely enormous🥇 now it won't be long before it seriously explodes 🧨 🧨 🧨
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
28 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·30 min sitten"THE NEW BEAST" HAS AWAKENED – ARE YOU READY FOR CIRCULAR DOMINANCE? 🦁🧬💎 If you were wondering if the hype is real, check today's headlines from Boston. BioWorld (the biotech bible) has just delivered its verdict: Circular RNA is "The New Beast" in gene and cell therapy. This is why those who sell now will bitterly regret it: 1. FROM THEORY TO INDUSTRIAL STANDARD 🏭 When the world's leading trade press uses words like "The New Beast", it means that mRNA 1.0 is about to be retired. Circio holds the keys to this new infrastructure. We're not talking about a small project, we're talking about the next technological monopoly. 2. THE 40X POWER THAT SHAKES BOSTON 💥 While you were reading the article, Circio presented poster data today confirming ~40x increased performance in heart tissue. These are numbers that make Big Pharma choke on their coffee. That's why we've got an ORAL PRESENTATION on Friday – the elite wants to hear it from the source. 3. THE VALIDATION TSUNAMI 🌊 • Acuitas collaboration: Checked. • 250 million in cash until 2030: Checked. • Global "Beast"-status: CONFIRMED. Status: Oslo Børs is taking a holiday, but the global biotech world has just hit the gas. We are in a company that is priced like a mosquito, but has the technology of a lion. Those who try to trade this in penny dips now are playing with matches in the middle of a gasoline explosion. We are not looking at the price. We are looking at the revolution. We know what we own. ♟️🧱🍷
- ·38 min sittenTHE MATH BEHIND AN EXPLOSION – ARE YOU GEARED FOR TRIPLE DIGITS? 🧮🚀💎 Stop guessing. Start calculating. Those who see Circio as a "small biotech" haven't understood how platform pricing works when the pieces fall into place. With ~238 million shares outstanding, this is the calculation that should keep the bears awake at night. Here is the Bull-Case Matrix, from realistic to total euphoria: 1. PLATFORM RECOGNITION (20–50 kr) 🏗️ When the market understands that circVec is not just a project, but infrastructure for the next generation of RNA. The ASGCT data validates us, partnerships land, and 5–10 billion in Market Cap becomes the new normal. This is not "insanity" – it's fair pricing of unique tech. 2. BIG PHARMA MANIA (80–160 kr) 🏛️🔥 This is where it starts to get fun. Multiple deals, Acuitas credibility and in-vivo CAR-T data hitting the bullseye. International funds come in and sweep up what's left of the shares. Oslo Børs can no longer price the case – we're talking strategic acquisition pricing. 3. THE MOON SHOT (300 kr+) 🌕 Full circular revolution. Acquisition interest from the biggest giants who must own the technology not to die out. This is the scenario where those who sold at 10 kr will cry for decades to come. WHY IS THIS HAPPENING NOW? ⚡ • Cash Runway: 250 million in the back until 2030. The brakes are removed. • Oral Presentation: We own the main stage in Boston. • Small Valuation vs. Enormous Potential: This is the discrepancy we are exploiting now. Important message: Biotech is not for cowards. It's psychology, it's volatile, and it's brutal. But when the technology is real, and the Fibonacci lines point upwards, then it's mathematical gravity that takes over. We are not looking at small change. We are looking at a repricing of historical dimensions. The calculation is made. The seed is sown. We know what we own. ♟️🧱🍷
- 1 t sitten1 t sitten·49 min sitten · MuokattuThis is absolutely enormous🥇 now it won't be long before it seriously explodes 🧨 🧨 🧨
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 719 | - | - | ||
| 794 | - | - | ||
| 54 | - | - | ||
| 58 | - | - | ||
| 4 206 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
28 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·30 min sitten"THE NEW BEAST" HAS AWAKENED – ARE YOU READY FOR CIRCULAR DOMINANCE? 🦁🧬💎 If you were wondering if the hype is real, check today's headlines from Boston. BioWorld (the biotech bible) has just delivered its verdict: Circular RNA is "The New Beast" in gene and cell therapy. This is why those who sell now will bitterly regret it: 1. FROM THEORY TO INDUSTRIAL STANDARD 🏭 When the world's leading trade press uses words like "The New Beast", it means that mRNA 1.0 is about to be retired. Circio holds the keys to this new infrastructure. We're not talking about a small project, we're talking about the next technological monopoly. 2. THE 40X POWER THAT SHAKES BOSTON 💥 While you were reading the article, Circio presented poster data today confirming ~40x increased performance in heart tissue. These are numbers that make Big Pharma choke on their coffee. That's why we've got an ORAL PRESENTATION on Friday – the elite wants to hear it from the source. 3. THE VALIDATION TSUNAMI 🌊 • Acuitas collaboration: Checked. • 250 million in cash until 2030: Checked. • Global "Beast"-status: CONFIRMED. Status: Oslo Børs is taking a holiday, but the global biotech world has just hit the gas. We are in a company that is priced like a mosquito, but has the technology of a lion. Those who try to trade this in penny dips now are playing with matches in the middle of a gasoline explosion. We are not looking at the price. We are looking at the revolution. We know what we own. ♟️🧱🍷
- ·38 min sittenTHE MATH BEHIND AN EXPLOSION – ARE YOU GEARED FOR TRIPLE DIGITS? 🧮🚀💎 Stop guessing. Start calculating. Those who see Circio as a "small biotech" haven't understood how platform pricing works when the pieces fall into place. With ~238 million shares outstanding, this is the calculation that should keep the bears awake at night. Here is the Bull-Case Matrix, from realistic to total euphoria: 1. PLATFORM RECOGNITION (20–50 kr) 🏗️ When the market understands that circVec is not just a project, but infrastructure for the next generation of RNA. The ASGCT data validates us, partnerships land, and 5–10 billion in Market Cap becomes the new normal. This is not "insanity" – it's fair pricing of unique tech. 2. BIG PHARMA MANIA (80–160 kr) 🏛️🔥 This is where it starts to get fun. Multiple deals, Acuitas credibility and in-vivo CAR-T data hitting the bullseye. International funds come in and sweep up what's left of the shares. Oslo Børs can no longer price the case – we're talking strategic acquisition pricing. 3. THE MOON SHOT (300 kr+) 🌕 Full circular revolution. Acquisition interest from the biggest giants who must own the technology not to die out. This is the scenario where those who sold at 10 kr will cry for decades to come. WHY IS THIS HAPPENING NOW? ⚡ • Cash Runway: 250 million in the back until 2030. The brakes are removed. • Oral Presentation: We own the main stage in Boston. • Small Valuation vs. Enormous Potential: This is the discrepancy we are exploiting now. Important message: Biotech is not for cowards. It's psychology, it's volatile, and it's brutal. But when the technology is real, and the Fibonacci lines point upwards, then it's mathematical gravity that takes over. We are not looking at small change. We are looking at a repricing of historical dimensions. The calculation is made. The seed is sown. We know what we own. ♟️🧱🍷
- 1 t sitten1 t sitten·49 min sitten · MuokattuThis is absolutely enormous🥇 now it won't be long before it seriously explodes 🧨 🧨 🧨
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 719 | - | - | ||
| 794 | - | - | ||
| 54 | - | - | ||
| 58 | - | - | ||
| 4 206 | - | - |
Välittäjätilasto
Dataa ei löytynyt